Lenalidomide Sandoz (Lenalidomide)

Lenalidomide acts on malignant plasma cells and related pathways in hematologic cancers.

• Multiple myeloma: improves progression‑free survival and overall response rates.
• Mantle cell lymphoma: used in combination regimens to achieve disease control.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and cytopenias.
• Follicular lymphoma (in combination therapy): contributes to higher response rates when added to standard chemoimmunotherapy.
• Chronic lymphocytic leukemia (investigational): being studied for potential efficacy in relapsed disease.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to anti‑proliferative, pro‑apoptotic and anti‑angiogenic effects, while also modulating cytokine production and enhancing natural killer and T‑cell immune responses against malignant cells.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: lowered platelet levels that may cause bleeding.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may lead to dehydration.
• Rash: mild skin irritation or redness.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe rash or Stevens‑Johnson syndrome: extensive skin involvement.
• Elevated liver enzymes: potential liver injury.
• Secondary primary malignancies: emergence of new cancers.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Lenalidomide requires careful monitoring and patient counseling to minimize risks.

• Monitor blood counts: perform regular CBCs to detect cytopenias early.
• Assess thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients.
• Avoid pregnancy: use effective contraception; the drug is teratogenic (Category X).
• Adjust for renal impairment: dose may need modification in reduced kidney function.
• Counsel on infection signs: educate patients to report fevers or infections promptly.
• Store below 25°C: keep in the original container, protect from moisture and direct light.

Lenalidomide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Thalidomide: additive toxicity, especially neuropathy and teratogenicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lenalidomide exposure.
• Anticoagulants (e.g., warfarin): heightened bleeding risk.
• Live vaccines: risk of uncontrolled infection due to immunosuppression.
• Hormonal contraceptives: reduced effectiveness, increasing teratogenic risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may lower drug levels.
• NSAIDs: potential for increased renal toxicity.
• Diuretics: monitor electrolytes and renal function.
• Immunosuppressants (e.g., cyclosporine): may enhance immunosuppression.
• Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.